EU Speedy Review Success For Kite But Not For Lilly

 
• By Maureen Kenny

KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib

Kite_Surfer_Beach
The EMA is speeding up its review process for Kite • Source: Shutterstock

More from Product Reviews

More from Pink Sheet